It will be equipped with the most advanced digital solutions and highest technological standards, including continuous manufacturing and laboratory automation, with a special attention to sustainability.
and confirms the importance of Switzerland as our prime hub for the manufacturing of biotech medicines,”
The pharma giant has invested more than one billion Swiss francs in Switzerland over the past ten years, reflecting the strategic importance of the country, where it employs more than 2,400 employees across nine locations.
“With this latest investment, Merck is taking one step further towards a strong positioning of the canton of Vaud as a Health Valley, which already includes 360 companies, 400 laboratories and 20,000 jobs,” says Philippe Leuba, State councillor for the canton of Vaud.
With the sites of Aubonne and nearby Vevey, Switzerland is Merck’s prime hub for manufacturing biotech medicines. With this latest expansion, Merck will have invested more than 1 billion francs (€800 million) in Switzerland over the past ten years, reflecting the strategic importance of the country, where it employs 2,300 employees across 11 locations.